key: cord-0766956-oandwntx
authors: Mofid, Sarah; Bolislis, Winona Rei; Brading, Clive; Hamilton, Nigel; Hardit, Cyril; Nagaoka, Makoto; Parain, Julien; Zanta, Maria; Kühler, Thomas C.
title: The utility of remote inspections during the COVID-19 health emergency and in the post-pandemic setting
date: 2021-10-13
journal: Clin Ther
DOI: 10.1016/j.clinthera.2021.10.003
sha: 69d17952f96f29ed6f382a39de9f991caceef5dd
doc_id: 766956
cord_uid: oandwntx

Purpose The COVID-19 pandemic has impacted the management and operation of regulatory agencies and the pharmaceutical industry around the world. It has prompted regulatory authorities to consider new ways of working and introduced, amongst others, remote inspections to validate the integrity of the regulatory data submitted by companies; evaluate the quality of production and manufacturing sites, and to ensure the conformity with Good Regulatory Practices with the overall goal of guaranteeing patient safety during the crisis. Method We summarize and discuss remote inspection guidelines and other related information made available by the Therapeutic Goods Administration (Australia), the European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency (Japan), the Medicines and Healthcare Products Regulatory Agency (UK), and the US Food and Drug Administration (US FDA). We also analyse the impact of the pandemic on inspections conducted by the inspectorates of the EMA and the US FDA. Findings The regulatory authorities that we studied all recognized the importance of implementing regulatory policies on remote inspections in response to the COVID-19 pandemic. The remote inspection guidelines from the five selected regulatory authorities aimed at mitigating the impact of pandemic but, while providing valuable advice to the pharma companies and being similar in intent, were not always aligned in terms of approach and solutions. Implications On-site inspections are likely to continue to be the norm and preferred standard for the foreseeable future. But the health authorities will need to further adopt a risk-based inspection approach and stimulate the increased uptake of inspection reliance as proposed by the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme not to overwhelm the pharma companies with repeat and redundant inspections. Remote inspections have proven to be a novel inspection tool, but it is important for health authorities to align on their approach on remote inspections in terms of methods applied and documentation requested.

The COVID-19 pandemic (SARS-CoV-2) has had profound impact on the management and operation of regulatory agencies and the pharmaceutical industry around the world. It has prompted regulatory authorities to consider new ways of working and has driven them to implement and adopt more agile or flexible approaches in order to maintain an efficient and functioning regulatory environment suited to meet the challenges of the pandemic. [1] Among those approaches adopted, is the use of remote inspections. They are not new, and the first remote inspection was conducted by the European Inspectorate already in 2009 [2] at a time where no official guideline had yet been developed.

Inspections are conducted by regulatory authorities, normally through face-to-face on-site inspections, in order to validate the integrity of the regulatory data submitted by companies; evaluate the quality of production and manufacturing sites, and to ensure the conformity with GRP (Good Regulatory Practices) with the overall goal of guaranteeing patient safety. Since the onset of the pandemic, regulators, and industry alike, have explored ways to continue with inspections, considering lockdown measures and travel restrictions put in place by various national governments.

Indeed, health agencies have shown a high level of reactivity in the face of the crisis. A review published in 2020 noted that around 22% of the documents published by health authorities were guidelines that aimed at providing recommendations and direction to manufacturers of medical products in order to minimize the disruption caused by the pandemic in conducting clinical trials or ensuring the supply of medicines for patients in need. [1] The current study summarizes the guidelines issued and processes adopted by five select regulatory authorities comprising the Therapeutic Goods Administration (TGA, Australia), the 

Data and information for this study, specifically on guidelines, were collected through the public databases of the TGA, the EMA, the PMDA, the MHRA, and the US FDA. These were included any information and all GXP guidelines comprising Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good pharmacoVigilance Practice (GVP) that we could find that was related to remote inspections in our analysis.

The above agencies were selected because of their active involvement in inspection activities around the world and for their pioneering adoption of remote inspections during the COVID-19 pandemic.

Additional and more granular information was also collected from the US FDA inspection database and the European Union Drug Regulatory Authorities Good Manufacturing Practice Database (EudraGMDP) to understand and visualise how the COVID-19 pandemic impacted regulatory inspections conducted by these, two of the worlds' largest, inspectorates. The information collected included, but was not limited to, the type of products concerned by the inspection (medicinal products for human use, investigational medicinal products, or products for veterinary use), the type of manufacturing operations concerned by the inspections, the clarifying remarks, the use of video conference, the conduct of a virtual site tour, etc. The analysis was done by investigating the number of inspections prior and during the COVID-19 pandemic (from January 2020 to March 2021) and identifying when alternative measures were used in the inspection process, including mutual recognition agreements, confidentiality agreements, remote inspections, or remote reviews.

A literature review was also conducted to complement the findings and discussions in the study. The preferred database to support our literature search was PubMed® (https://pubmed.ncbi.nlm.nih.gov/) which we interrogated with the search phrases such as "mutual recognition agreement", "GMP inspections" and "Good Manufacturing Practice". Table 1 presents guidelines on remote inspections released by the five regulatory authorities   in scope of this study (EMA, US FDA, MHRA, PMDA, and TGA) during the COVID-19 pandemic. The UK MHRA was the first regulator to release a guideline on good inspection practices (covering GXP) during the COVID-19 crisis, [3] followed by the EMA, [4] [5] [6] [7] the US FDA, [8] [9] the TGA, [10] [11] and the PMDA. [12] [13] While each guidelines has its own specificities, including the wording related to remote inspections, they all have in common that they offer information to pharma companies the help them adapt their ways of working on how the inspection processes should be modified by the fact that they will be conducted remotely.

The TGA published two major guidelines detailing expectations on overseas inspections that could either be conducted as fully remote inspection or as hybrid inspections. The EMA published specific guidelines on the topic of remote inspections, taking into consideration the specificities of pharmacovigilance, good clinical practices, and good pharmaceutical practices. The FDA guidelines were already expected for quite some time, and after allowing a certain number of regulatory flexibilities, the FDA finally authorized the conduct of remote inspections and provided guidelines on the conduct of them. The MHRA positioned itself as an innovative agency and shaped the regulatory landscape by publishing the first COVID-19 remote inspection guidelines. The PMDA issued procedures not only for remote GCP inspections but also issued Good Post-marketing Study Practice (GPSP) guidelines to meet the COVID-19 pandemic.

While not shown in Table 1 , it is also important to note the work of Russian State GMP Inspectorate which, since the onset of the pandemic, appears to have a strong focus on remote inspections as evidenced by that they have conducted a total of 111 remote inspections with an established legal basis to conduct them. [14] Remote inspections guidelines published by select Health Authorities [12] THE EUROPEAN MEDICINES AGENCY APPROACH

The first remote inspection, conducted by a European Agency was done by the French National Authority for Health (L'Agence nationale de sécurité des medicaments et des produits de santé, ANSM) in 2009. The remote inspection was conducted on a manufacturing site in Pennsylvania, United States. [15] At that time, no specific guideline had yet been developed on remote inspections.

Prior to the COVID-19 pandemic, the only guideline on remote inspections available within the EU was the Pharmacovigilance remote inspection guideline from 2012, cf. Figure 1 , lower panel. [7] This guideline provides information on instances when regulatory authorities may need to opt for alternative methods to conduct risk-based inspections when there is a need to prioritise, reduce, or postpone certain inspections related to pharmacovigilance activities. The guideline has since been updated in 2020. The updated version provides more detailed information on how to prepare for inspections and is aligned with other available guidelines on remote inspections that since then have been released.

The COVID-19 pandemic has served as a catalyst for additional remote inspection guidelines being released in the EU, cf. Figure 1 , lower panel. In April 2020, the EMA published a guideline in the form of a question and answer (Q&A) document addressing the impact of the COVID-19 pandemic on its regulatory activities, including those relating to inspections, and provides advice to stakeholders on the implementation of specific flexibilities to ensure the continuity of regulated activities. [4] This guideline has been updated by the EMA on a regular basis as a means for the regulator to rapidly issue advice to companies on specific topics. [16] In the Q&A document, the EMA extended the validity of most Good Manufacturing Practices (GMP) certificates until the end of 2021, which significantly reduced the number of required inspections for the agency. Extending the validity of GMP certificates aims to reduce the effect that international travel limitations have on product batch releases for which inspections are required. The guideline reminds manufacturers, and the industry as a whole, of their responsibility and legal obligations to respect and comply with GMP provisions to furnish quality medicines to patients, even when surveillance and routine on-site inspections have been suspended.

Remote GMP inspections are explicitly addressed in this early guideline through what is referred to as "distant assessment". More specifically, it states that a distant assessment may be conducted for new sites inside or outside the European Economic Area that have never been inspected nor authorised in order to evaluate if it could be authorised without an on-site pre-approval inspection. [4] Since the release of the Q&A document, several other guidelines have been drafted to incorporate information on remote inspections. This includes the guideline on remote GCP (Good Clinical Practice) inspections during the COVID-19 pandemic [5] and the guideline related to GMP/GDP (Good Distribution Practices) and Plasma Master Files (PMF). [6] The guideline on remote GCPs outlines the process that should be established to allow for the review of documents, facilities, records, and any other resources that are deemed by the authorities to be related to the conduct of a clinical trial and should be provided by the sponsor of the clinical trial. On the other hand, the guideline related to GMP/GDP and PMF distant assessments [6] specifies the scope of the remote inspections and outlines the general steps that will take place during a remote inspection, including feasibility assessments, preparation steps, the actual remote inspection activities, and other postinspection requirements or activities.

In the different guidelines that the EMA has issued, and in the EudraGMDP, the agency refers to remote inspections as "distant assessments", defined as "the assessment of the compliance of a site with the Union GMP/GDP principles performed by officials of Union Competent Authorities on the basis of documents and interviews and supported by technology for communicating, accessing systems, sharing and reviewing documents and other information, without the inspectors being physically present at the sites where the activities subject to the assessment have taken place and where the inspection would ordinarily be hosted". [6] In general, the feasibility of a remote inspection is evaluated before any decision to actually conduct one is made. The feasibility assessment does consider the following technical aspects: appropriate platforms, use of teleconference and videoconference, live sharing of screens displaying read-only access systems, live camera footage or video recording of the sites, time zones, and specific languages used [6] . In August 2020, similar to the EMA, the US FDA published a Q&A document [9] addressing inspections during COVID-19, in which it reaffirmed its commitment to provide timely guidelines and support on specific issues faced during the pandemic, including on how inspections would be impacted by and what types of inspections would be considered "mission-critical".

On-site inspections considered as "mission critical inspections", or those that may influence the health security of U.S. patients, are prioritized. Several factors are considered when determining whether an inspection qualifies as "mission critical" or not, namely if the product is a breakthrough designated therapy; a regenerative medicine advanced therapy designated one [17] ; or is used to diagnose, treat, or prevent a serious disease or medical condition for which there is no other appropriate substitute. [9] For-cause and pre-approval inspections also qualify as mission-critical inspections. Forcause inspections are triggered by a specific problem that has come to US FDA's attention, [18] for instance, issues related to data integrity and validity, [19] while pre-approval inspections are conducted after a company submits an application to the US FDA to market a new product or to approve a new plant installation. [18] In terms of inspecting non-mission critical manufacturing sites, the US FDA has adopted a variety of tools and processes, including assessments based on existing inspection reports provided by other inspectorates, or information and records obtained directly from the applicants. [20] In a recent update to the August 2020 Q&A guideline [9] the US FDA specified that it is working directly with the facilities to communicate issues identified through a review of requested records and that they will consider responses from the facilities before taking any action on a pending application, such as for instance documentation of corrective actions that should be implemented by the site.

In a recent communication, the US FDA discusses the use of technologies and tools for remote inspection at overseas sites [21] including but not limited to a review of historical compliance documents of facilities (recalls, product complaints, etc.), information shared by trusted states, or local and foreign regulatory partners (Mutual Recognition and Confidentiality Agreements). [21] In addition to the above the US FDA decided to also include alternative tools and resources to assess manufacturing site GMP compliance. [21] These alternative tools were introduced after the US FDA initially announced a return to domestic on-site inspections in July 2020 [22] and after the US Government Accountability Office (GAO) published a report on January 2021, [23] which included recommendations specifically to the US FDA on addressing backlogs of inspections and ensuring regular inspection activities to help meet drug oversight objectives. Measures included the use of remote interactive evaluations through remote livestreaming video, teleconferencing or screen sharing. In fact, the US FDA adopted a riskbased approach on the use of live footage and live touring of facilities. This was first implemented at human and animal food production facilities, and then progressively extended to medical device inspections. [24] For medical devices, the US FDA released a guideline in April 2020 (updated in December 2020) on the Extension and Expansion of Temporary extraordinary measures related to MDSAP audits during covid-19 quarantine orders and travel restrictions -Remote audits [25] . This guideline communicates the agency's position on the conduct of remote audits of medical device facilities. The MDSAP (Medical Device Single Audit Program), created by the IMDRF (International Medical Device Regulators Forum) [26] , allows firms to undergo one audit by an accredited third party to satisfy quality regulations for the US, Canada, Brazil, Japan, and Australia.

The updated guideline released in December 2020 [25] provides information on four types of remote or hybrid audits performed by the US FDA under the MDSAP. These are 1) a desktop audit, which is an audit performed remotely through a review of documentation, 2) a remote audit, which is an audit performed off-site using information and communication technology (ICT), 3) a hybrid audit, which is partially performed off-site using ICT and partially performed on-site by at least one qualified MDSAP auditor, or 4) a surrogate audit, which is partially performed off-site using ICT and partially performed on-site by at least one qualified non-MDSAP auditor.

Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency [27] , the US FDA re-defined remote inspections as remote interactive evaluations, which refers to the use of any combination of interactive tools such as remote livestreaming video of operations, teleconferences and screen sharing for pre-approval inspections, pre-license inspections, post-approval inspections, surveillance inspections, follow-up and compliance inspections, and bioresearch monitoring inspections. [28] Technological requirements are extensively discussed in this US FDA guideline to ensure that the overall quality is sufficient and adequate to remotely review, observe, examine, and evaluate the documentation requested. [27] In May 2021, the US FDA published a report describing its inspections performance during the pandemic and laying out the agency's roadmap on inspections going forward. [29] The report notes that the US FDA will continue to conduct most mission-critical inspections and prioritized surveillance inspections but that other types of inspections that do not match these criteria may be postponed due to the pandemic. The roadmap discusses three scenarios for future inspections (a base case, a best case, and a worst-case scenario) which will depend on the emergence of virus variants and the upholding of travel restrictions. In all three scenarios, the US FDA would remain agile and nimble through, for instance, the use of remote interactive evaluations and livestreaming video of drug manufacturing facilities [27]) or prioritizing inspections that have an impact of the product's availability or public health.

[29]

The MHRA published its first guideline on remote inspections in March 2020 [30] , which in the meantime has been withdrawn and replaced with an updated guideline [31] in connection with that the MHRA recently announced that they would resume on-site domestic inspection.

In the first guideline the MHRA's established their definition of remote inspections as "organisations being asked to provide electronic copies of documents and other information for review off-site, with teleconferences and email to follow up". [32] The guideline also describes the use of alternative approaches for routine regulatory oversight, such as officebased inspections [3] which is an audit conducted through a collaboration between the applicant and the inspectorate, during which electronic copies of documents are requested and reviewed remotely [33] and could also involve teleconferencing. However, it does not mention whether a virtual live tour of the facility would be in scope or not.

The MHRA did recognize the importance of the Pharmaceutical Inspection Convention (PIC) and Pharmaceutical Inspection Co-operation Scheme (PIC/S) reliance procedures [33] during the COVID-19 pandemic. Though these collaborations 56 inspectorates across the globe coordinate efforts through mutual recognition agreements and confidentiality arrangements.

The MHRA also established an incident group, comprising members of the Inspectorate Strategy and Innovation Unit to provide expert advice to the agency's COVID-19 task force addressing technical and regulatory issues raised by stakeholders on remote inspections.

[33]

In the third quarter of 2020, the PMDA amended two guidelines related to GCP and Good

Post-marketing Study Practice inspections. [12] These amendments were introduced to describe the detailed procedure of remote inspections, clarify how to proceed with the necessary documentation, and reflects expectations on video conferencing systems. In November 2020, the PMDA released an English translation of their new guideline on conducting remote inspections for drugs and regenerative medical products and is the first PMDA guideline to advise on the conduct of remote inspection. [12] Digitalization is at the core of the guideline and it mentions the use of a cloud-based systems and video conferencing tools to facilitate the remote review of documents.

Remote inspections conducted by the PMDA are divided into two phases: 1) the preinspection and 2) the main inspection phase. During the pre-inspection phase, several quality documents are shared with the regulatory authority. Sharing quality documentation with the inspectors can be done through the use of external data storage media such as CDs or DVDs, or through a cloud-based platform, at least ten days before the main inspection.

During the pre-inspection phase, inspectors review the documentation provided by the applicant and identify the target areas that they would like to focus on during the main inspection phase. As for the main inspection, the PMDA contacts the applicant by phone or e-mail to inform them of an on-site inspection or, due to sanitary circumstances, a remote inspection.

As discussed in the Procedure for Remote Inspection section, which is part of the compliance inspection on drugs and regenerative medicine products guideline, the PMDA inspectors are not open to live footage tours of facilities.

In two guidelines on remote inspections, [10] [11] the TGA underscores the importance of compliance with GMP-standards, even when inspections are postponed. They emphasize the importance of a close collaboration and communication with manufacturers of medical products to guarantee the safety, quality, and efficacy of health products. To this end, the TGA requires that a "remote inspection host" is nominated at the manufacturing facility. This person would be the single point of contact for the TGA for any questions or problems that need to be sorted.

The to-be-inspected site must establish a strategy as soon as the notice of the inspection and the pre-inspection checklist has been communicated. Documentation following a predefined checklist has to be provided by the manufacturer and helps the TGA to determine if a remote inspection is considered feasible or not. Table 2 shows the documentation that must be made available to the TGA according to the inspection checklist. The documentation requested depends on the level of risk that the manufactured products represent. The checklist, and the associated documentation, has to be shared with the TGA within 2 weeks of the receipt of the notification of an inspection.

Inspection checklist issued by the Australian TGA Table 2   Table 2 . Three examples of documents (for non-sterile and sterile products, and for contractors) required by the TGA for Compliance Verification Assessments (remote inspections). Source: Authors' elaboration based on TGA publications. [34] [35] In preparation for an inspection, the TGA requires manufacturers to prepare a virtual tour of relevant areas by pre-recorded videos of the site and its operations to allow the inspectors to visualise the site ahead of the actual remote inspection. How to handle time zones, language differences, and other technical and practical barriers during the inspection are outlined in the guideline and need to be properly addressed and prepared for by the manufacturer.

Regarding the Quality Management System (QMS), the inspectorate requires a read-only access to the QMS to review any complaints, deviations, and out-of-specifications as they deem fit.

During the pandemic, remote inspections conducted by the TGA were first performed on domestic facilities and then extended to overseas facilities following the successful experience gained at domestic level.

The TGA noted that "2,700 overseas manufacturers rely on desk-top clearance and the experience has been very positive." [36] A re-inspection is only decided in borderline cases as well as when the dosage form is different. The EudraGMDP allows for a more specific breakdown of the type of remote inspection conducted. The pie chart in Figure 3 shows the distribution of remote inspections versus remote inspections conducted with live footage between January 2020 and April 2021. These inspections resulted in 121 GMP certificates being issued and an analysis of these certificates revealed that five were related to vaccines manufacturing sites while the remaining ones were related to pharmaceutical products. Ireland (21%) were the most active inspectorates and accounted jointly for 78% of the total number of remote inspections carried out during the pandemic. In 2018, the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) guideline on GMP Inspection Reliance, which was based on an ICMRA draft, entered into force. [44] This guideline has served as a basis for practical solutions to GMP inspections during the COVID-19 pandemic. It has laid out a general process for remote inspections, such as for how to conduct remote inspections of overseas facilities and has identified instances where an acceptable level of GMP compliance could be confirmed and assured by activities of another regulatory authority or other authorities without the need for a repeat on-site inspection.

Indeed, this guideline aimed to establish appropriate GMP inspection processes from the convenience of a desktop.

The results section of this study lends evidence towards that the guidelines from the five selected regulatory authorities on remote inspections all aimed at mitigating the impact of COVID-19, but, while similar in intent, were not always aligned in terms of approach and solutions. Indeed, while the guidelines issued covered the full range of GXP-inspections, as evidenced by Table 1 , there was no uniform division, approach, or timing by which the different HA chose to publish their remote inspection guidelines making it hard to draw any meaningful conclusion at such granular level. Notwithstanding this, these authorities provided Indeed, the adoption of remote inspections was driven by one common objective: to ensure health security for all citizens by limiting the disruption of supply chains, notably for essential medicines. This is an important evolution because a rather large proportion of Active Pharmaceutical Ingredients (API) and Drug Products (DP) these days are being produced in, and procured from, developing countries. [46] According to an earlier analysis by Bolislis and al [1] , the medicine and medical devices supply chain was severely disrupted during the pandemic. The main reason for this was the closing of borders between countries which prevented APIs to arrive in DP manufacturing sites. Low-and middle-income countries have been particularly impacted by shortages as discussed in Reference [47] .

In response to constraints on API supplies, the European Commission put forward a proposal for a regulation [48] to reinforce the role of the EMA, especially in relation to mitigating shortages. In a statement on Safeguarding Pharmaceutical Supply Chains in a Global Economy [46] the FDA noted that the production of APIs has progressively been offshored to China (13% of worldwide API production occurs in China) and India (18% of the worldwide API production), which has increased the US' and EU's dependence on these countries. For this reason, remote inspections have become an attractive option for regulatory authorities to partially address manufacturing and supply chain constraints, especially in a pandemic travel restricted setting.

The MHRA has pushed the regulatory science envelope rather significantly on remote inspections in as much that they have conducted more than 750 remote GXP inspections during the pandemic [49] . The MHRA also chosen to uphold their international inspections program and performed inspections in Canada, the US, Central and South America, Africa, Eastern Europe, Commonwealth of Independent states, the Middle East, the Pacific, Asia, Australia and New Zealand. The inspectorate modified its ways of working and tested and implemented a wide variety of methods. [33] According to the MHRA, these new ways of working are to be maintained, as they have decided to continue performing desktop assessments according to a risk-based program. [33] According to a GAO-report the US FDA may face an inspection backlog if the agency continues to postpone them and continues to prefer on-site inspections over deploying alternative tools such as conducting inspections remotely. [23] . The GAO-report noted that at the end of the pandemic, establishments that have never been inspected, or that have an outdated inspection (>5 years), should be prioritized. The risk, however, is that the establishments identified by this model may not be inspected in a timely manner. [23] The US FDA is actively tracking the sites that need to be inspected and noted that the size of the backlog will depend on the extent to which alternative inspection tools are used. To cope with the backlog, the US FDA recently published a guideline stating that they will use alternative (remote) inspection tools. [21] Remote inspections undoubtedly come with some technical challenges. For instance, to facilitate the live remote monitoring of a manufacturing site, it is important to have a stable internet connection with sufficient bandwidth. This can be an issue for manufacturing sites located in areas that lack the required infrastructure to support high speed internet connection. This should in principle be an addressable obstacle of transient nature that eventually would be overcome as the internet grid is continuously expanded and upgraded.

Another consideration is that abundant metal pipes and production steel vessels at production sites can cause signal perturbation or blind spots.

Other considerations in this regard include availability of secure digital drop boxes, limits to the size of e-mail attachments, access to contemporary video conferencing tools, or firewall security settings. The above is a minimum of items that should be addresses before any remote inspection can be planned and executed.

Few did imagine that remote inspections would become a reality, but many companies were compelled to go virtual with audits and move operations to the cloud. As an illustration, the head of regulatory CMC operations at a company claimed that it has hosted more than 60 on-site, virtual, and hybrid inspections from 15 agencies during the pandemic. [50] The pursuit and implementation of a robust QMS, that is an integral part of the corporate culture, is at the heart of patient safety and therefore a top priority to pharmaceutical companies. This is conducive, and possibly a prerequisite, towards stimulating the further uptake and wider implementations of remote inspections. The importance of ingraining a quality mindset in pharma operations has been spearheaded by the US FDA through several communications over the recent past. [51] [52] OPPORTUNITIES AND CONSIDERATIONS Regulatory agencies are under mounting pressure to improve performance and facilitate timely access to safe, effective, and quality medicines. This has become increasingly challenging during the COVID-19 pandemic with growing public expectations and political pressure. The introduction and adoption of remote inspections during the COVID-19 pandemic is one example of regulators demonstrating resilience and agility in the face of a crisis. Notwithstanding this, some regulators are eager to resume onsite inspections once the pandemic is over and argue that these are much better suited to uncovering violations of GXP-practices. [53] .

The PIC/S guideline on GMP inspection reliance was introduced in response to the limitations of onsite inspections imposed by the pandemic. Through this, regulatory authorities could avoid duplication of work, reduce the regulatory burden experienced at manufacturing sites, and allow for prudent stewardship and more efficient deployment of global inspection resources. Through reliance, the requesting agency can trust an assessment (of the GMP compliance of the manufacturing site) conducted by a national or a local competent authority to evaluate if the level of compliance can be confirmed without the need for a repeat on-site inspection. The importance of regulatory reliance is nicely summarized by the Australian Government: "…if a system, service or product has been adopted under a trusted international standard or risk assessment, no additional requirements should be imposed for approval…" [55] Indeed, PIC/S member inspectorates could prioritize domestic inspections, which could then be relied upon by the other members and would make repeated inspections unnecessary.

The total number of inspections could be reduced, and resources redirected to inspect facilities with either high risk operations or facilities that never have been inspected before.

Moreover, we believe it would be beneficial to the sector, and the patients it serves, to encourage the extension of the current inspection Mutual Recognition Agreement to cover additional product types including vaccines, plasma-derived medicines, and investigational medicinal products as is anticipated to occur by 15 July 2022. [56] This allows for a rapid evaluation of documentation and exploration of topics of interest.

Conversely, a remote inspection requires manufacturers to set aside significant resources in terms of staff and time to list, scan, sometimes translate, and upload a high number of diverse documents that are requested before and after the actual inspection.

Notwithstanding the above, new models and paradigms emerge, one is the "hybrid inspection" scheme, in which the authority sends a (local) inspector to the site while the rest of the inspection team would conduct the inspection remotely. The front-line inspector on site can effectively gauge the totality of information and identify issues by virtue of physically being on site. S(he) can quickly browse information and zoom in on specifics and hand that over to the remote inspector colleagues for a deeper analysis.

Remote inspections have proven their value and there are instances when they fill a purpose. The global population could experience further manifestations of the pandemic that could lead to an increase in caseloads and hence a need to dramatically increase the availability of (a) particular drug(s) and regulatory authorities may need to inspect facilities to quickly mitigate shortage situations. Alternatively, there may be situations where on-site visits are not possible and remote access is preferred, for instance when travel restrictions have been put in place, when the security situation is questionable, or when entry VISAs are hard to obtain.

Notwithstanding this, the sector has developed a well-functioning and proven inspection management system which prior to Covid-19 was routinely used to host very many on-site inspections each year. While remote inspections have proven their value in certain circumstances and now must be considered to be part of the regulatory armamentarium, we don't think they should become the default modus operandi yet and believe on-site inspections should still play a key role.

To many inspectorates, remote inspections are rather new and the standards by which they are conducted are still diverse both in terms of process methodology applied and range of supporting documents demanded. To limit the resource burden associated with preparing for remote inspections, it is important for the health authorities to align on their approaches and methods, in particular regarding the pre-remote-inspection documentation requested.

We suggest using available standard documents such as the Documentation Master File format alternatively another pre-established and agreed set of documents such as the Site Master File or the Annual Product Quality Review (which includes many of the most frequently requested documents such as variations, complaints, recalls, deviations, etc.). We would be rather agnostic as to the chosen documents as long as a practical consensus is achieved. This is important because the number and types of documents that need to be submitted in front of a remote inspection are often greater than those typically requested during an on-site inspection. The situation is further complicated because documents sometimes need to be translated and furnished with very short timelines. So far, no uniform or agreed remote inspection model has emerged but different agencies have implemented their own approaches -each one with its own pros and cons. For remote inspections to be performed as efficiently as possible, we believe it is important that health authorities work on aligning and synchronizing their respective approaches when it comes to remote inspections. This should include the pre-read documentation packages that was already discussed but also inspection methodologies, tools, and technologies that are used during the remote inspection process.

Similarly, important is that intellectual property, proprietary art, and confidential data can be properly safeguarded and cyber secured, as more and more information is being exchanged across cloud-based systems between the inspected entity and the inspectorate and duplicated at health authority levels.

And on a final note, it is central to recognize that remote inspections be regarded as having the same standard as on-site inspectionsnot requiring a second follow up on-site inspection because of perceived lower standards. The outcome of a remote and an on-site inspection should be the same and carry an equivalent quality stamp.

Prior to the COVID-19 pandemic, remote inspections were considered but their utility and implementation had not been demonstrated and they were still far from commonplace.

Precipitated by the pandemic, regulatory authorities and industry alike, have quickly adopted the use of alternative methods to ensure business continuity and to guarantee the availability of medical products for patients around the world. One such value adding regulatory agility that was introduced during the pandemic that has served its purpose, and hence society and patients, during the acute health crisis, was the introduction of remote inspections that allowed regulators to verify compliance of site operations in accordance with applicable laws and regulations. While remote inspections may not fully substitute on-site inspections, they have proven their value and should accordingly remain a tool in the regulatory toolbox as we move into a post-pandemic setting.

Having said that, we believe the best way forward for the sector, and the patients it serves, is a) to increase the uptake of GMP inspection reliance, b) for on-site inspections to continue to play a key role, and c) for health authorities to align on their approach to remote inspections in terms of methods applied and documentation requested. Live footage used in COVID-19 remote inspections [39] Number of 483 Forms issued before and during the pandemic [35] 

Regulatory agilities in the time of COVID-19: Overview, Trends and Opportunities

New arrangements for MHRA Good Practice (GxP) inspections due to coronavirus (COVID-19

Guidance on remote GCP inspections during the COVID19 pandemic

Medicine Agency, «Guidance related to GMP/GDP and PMF distant assessment

Medicine Agency, «Remote pharmacovigilance inspections of MAHs during a crisis situation-Points to consider

Supply Chain, and Drug Inspections | COVID-19

Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers Guidance for Industry

Therapeutic Good Administration, «TGA expectations for overseas manufacturing sites hosting remote inspections during the COVID-19 pandemic

Therapeutic Good Administration, «GMP approach to overseas manufacturers of medicines and biologicals during the COVID-19 pandemic

Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products

Inspectorate Weighs in on Remote Audits and International Harmonization

CERTIFICATE NUMBER :HMP/PT/38/2010 issued by French Health Authority ANSM

Notice to stakeholders Questions and answers on regulatory expectations for medicinal products for human use during the covid-19 pandemic

Regenerative Medicine Advanced Therapy Designation

designation#:~:text=As%20described%20in%20Section%203033,therapy%20(RMAT)

What does FDA inspect

Reasons for "For-Cause" Inspections in Bioequivalence Studies Submitted to the Food and Drug Administration

Guidance for Industry on Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

s Ongoing Use of Inspectional Tools for Ensuring Access to Safe, Quality Food and Medical Products During the COVID-19

COVID-19) Update: FDA prepares for resumption of domestic inspections with new risk assessment system

United States Government Accountability Office Report to Congressional Committees, «COVID-19 Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal Attention

FDAnews' 15th Annual Inspections Summit, «Keynote Address: The FDA Perspective on Inspections: What's Happening Now and What to Expect in 2021

Food and drug administration, «Extension and Expansion of Temporary extraordinary measures related to MDSAP audits during covid-19 quarantine orders and travel restrictions -Remote audits

IMDRF

Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency

Provides Guidance on Remote Interactive Evaluations for Oversight of Drug Facilities During COVID-19

Medicines and Healthcare products Regulatory Agency, «New arrangements for MHRA Good Practice (GxP) inspections due to coronavirus (COVID-19)

Medicines and Healthcare products Regulatory Agency, «Guidance for industry on MHRA's expectations for return to UK on-site inspections

GxP) inspections during the COVID19 outbreak

GxP) inspections during the COVID19 outbreak

«GMP clearance for overseas manufacturers

Regulating medicine manufacturers: is an on-site inspection the only option? The Australian approach to meeting inspection demands

EudraGMDP Database, «EudraGMDP Database,» 15

FDA inspection dashboard

Remarks at the Food and Drug Law Institute Annual Conference

FDA Form 483 Frequently Asked Questions

ICMRA aims for international alignment on policy approaches and regulatory flexibility during COVID-19 pandemic

PIC/S guidance on GMP inspection reliance based on draft by ICMRA with aim to maximise inspection resources for GMP compliance of overseas facilities

«Safeguarding Pharmaceutical Supply Chains in a Global Economy

Peters et Louise C, «Global resource shortages during COVID-19: Bad news for low-income countries

«Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on a reinforced role for the European Medicines Agency in crisis preparedness and

MHRA GCP Inspectorate Operations Manager and Senior GCP inspector, «Inspectors grounded -a year of innovation

Genentech's head of CMC regulatory for biologics development

Digital Technologies as a Key Enabler to Meet the Current and Future

Associate Director, Office of Manufacturing and Product Quality Office of Compliance Center for Drug Evaluation and Research FDA, «Current Expectations for Pharmaceutical Quality Systems

Statement from FDA Commissioner Scott Gottlieb, «Statement from FDA

on new steps to strengthen and modernize agency's oversight and reporting of inspections for sterile injectable drugs

Regulators discuss expectations and challenges in conducting virtual inspections

2020 ISPE Europe Annual Conference

Australian Government -Department of the Prime Minister and Cabinet

«International Standards and Risk Assessments

Mutual recognition agreements (MRA

The expert feedback and valuable editorial suggestions on the manuscript provided by David Doleski, Head of Global Quality Audit, Sanofi, are greatly appreciated. The authors' employer has kindly covered the publishing fees but has not been involved in the design of the study, in the collection, analysis, and interpretation of data nor in writing up the results or in the decision to submit the article for publication. 

All authors are Sanofi employees and may hold shares and/or stock options in the company.

All authors hold positions within the pharmaceutical industry, but they have not received any grant, honoraria, or other compensation to author this paper. The study was conceived of, executed on, and written up in the course of the authors' daily job.